Development
Boston Scientific Corporation
BSX
$102.43
-$0.67-0.65%
NYSE
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Revenue | 3.73B | 3.53B | 3.60B | 3.39B | 3.24B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 3.73B | 3.53B | 3.60B | 3.39B | 3.24B |
| Cost of Revenue | 1.16B | 1.11B | 1.07B | 1.05B | 1.02B |
| Gross Profit | 2.57B | 2.42B | 2.53B | 2.34B | 2.22B |
| SG&A Expenses | 1.38B | 1.24B | 1.35B | 1.22B | 1.16B |
| Depreciation & Amortization | 208.00M | 208.00M | 210.00M | 203.00M | 199.00M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 3.11B | 2.92B | 2.99B | 2.81B | 2.72B |
| Operating Income | 617.00M | 609.00M | 606.00M | 583.00M | 526.00M |
| Income Before Tax | 504.00M | 609.00M | 426.00M | 445.00M | 395.00M |
| Income Tax Expenses | 1.00M | 105.00M | 156.00M | 131.00M | 255.00M |
| Earnings from Continuing Operations | 503.00M | 504.00M | 270.00M | 314.00M | 140.00M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 1.00M | -- | -- | -- | -- |
| Net Income | 504.00M | 504.00M | 270.00M | 314.00M | 140.00M |
| EBIT | 617.00M | 609.00M | 606.00M | 583.00M | 526.00M |
| EBITDA | 930.00M | 909.00M | 904.00M | 868.00M | 820.00M |
| EPS Basic | 0.34 | 0.34 | 0.18 | 0.21 | 0.09 |
| Normalized Basic EPS | 0.25 | 0.23 | 0.22 | 0.22 | 0.22 |
| EPS Diluted | 0.34 | 0.34 | 0.18 | 0.21 | 0.09 |
| Normalized Diluted EPS | 0.24 | 0.22 | 0.22 | 0.22 | 0.22 |
| Average Basic Shares Outstanding | 1.47B | 1.46B | 1.45B | 1.44B | 1.43B |
| Average Diluted Shares Outstanding | 1.48B | 1.48B | 1.46B | 1.45B | 1.44B |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | 0.00% | 0.00% | 5.19% | 4.46% | 9.29% |